Hutch News

Hutch News

Stories tagged 'T cell'

Patients with advanced lymphoma in remission after T-cell therapy

New study: 7 of 11 trial participants who got two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission

Sept. 7, 2016 | By Susan Keown / Fred Hutch News Service

Seven of 11 trial participants who got a two-drug combination chemo plus intermediate dose of engineered T cells went into complete remission, a new study found.

View story >


Investing in the future

Five researchers get surprise grants through new President’s Young Investigator Awards

June 27, 2016 | By Sabin Russell / Fred Hutch News Service

This spring, five “young investigators” working at the Seattle cancer research center ― or soon to join it ― received entirely unexpected notes from Fred Hutch president and director Dr. Gary Gilliland. And the notes carried a bigger surprise. Each scientist had been awarded a $100,000 grant for “unrestricted” research in their laboratories.

View story >


Dramatic remissions seen in immunotherapy trial of blood cancer patients

Experimental, living T-cell therapy shows promise for treating advanced disease, making immunotherapy a ‘pillar’ of cancer care

Feb. 16, 2016 | By Andrea Detter / Fred Hutch News Service

Many patients with advanced blood cancers who are receiving experimental, “living” immunotherapy as part of a clinical trial are experiencing sustained remissions, according to preliminary results of the ongoing study at Fred Hutchinson Cancer Research Center.

View story >


Immunotherapy for pancreatic cancer boosts survival more than 75 percent in mice, study finds

Therapy using engineered immune cells offers promise for the ‘disease that desperately needs something new’

Oct. 29, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

A certain type of immunotherapy can boost survival from the nearly-always deadly pancreatic cancer by more than 75 percent in mice, a new study finds.

View story >


Scratching the surface of a rare skin cancer

Immune-boosting therapy shows promise for advanced Merkel cell carcinoma

Oct. 6, 2015 | By Dr. Rachel Tompa / Fred Hutch News Service

Skin cancer researcher Dr. Paul Nghiem is leading a clinical trial testing the immunotherapy drug pembrolizumab for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer. Early results from the trial are showing great promise for these patients.

View story >


An easy pairing

Fred Hutch’s Harlan Robins develops a new method to match thousands of pairs of key genes needed for cancer immunotherapy

Aug. 19, 2015 | Dr. Sabrina Richards / Fred Hutch News Service

Fred Hutch’s Harlan Robins has developed a new method to quickly and easily match thousands of pairs of key genes needed for cancer immunotherapy

View story >



GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Hutch Magazine
Our quarterly magazine

Annual Report
Fiscal year highlights

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.